Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

The Michael J. Fox Foundation Extends Funding for KineMed’s Brain-Process Biomarker Research for PD

Published: Friday, June 29, 2012
Last Updated: Friday, June 29, 2012
Bookmark and Share
KineMed receives $1.2 Million reinvestment from The Michael J. Fox Foundation for the further development of kinetic biomarkers predictive of Parkinson’s disease changes ahead of symptoms.

KineMed, Inc. has announced a further award of $1.2 Million from The Michael J. Fox Foundation towards the ongoing development of kinetic biomarkers that drug developers can use to accelerate and reduce the cost of trials of treatments for Parkinson’s disease (PD).

“The lack of validated biomarkers for Parkinson’s disease is a major hurdle to PD drug development today and so, our Foundation is invested in this critical research,” said Mark Frasier, Ph.D., Vice President, Research Programs for The Michael J. Fox Foundation for Parkinson’s Research.

Frasier continued, “KineMed’s cross-sectional study will look to confirm existing data that we have funded, which has identified biomarkers that are sensitive to subtle changes early in the disease process.”

“We are proud to be extending our work with The Michael J. Fox Foundation and thank the Foundation for this ongoing commitment which recognizes that the development of better biomarkers plays a key role in accelerating progress towards a cure for Parkinson’s disease,” said Dr. Patrizia Fanara, Ph.D., Vice President of Neuroscience, KineMed.

Dr. Fanara continued, “The current difficulty in advancing a cure is the pharmaceutical industry’s challenge to appraise the myriad proposed treatment strategies in concise, cost-effective trials. Our cerebrospinal fluid kinetic biomarkers measure the rate of neurodegeneration in PD patients within weeks, much sooner than any visible effect in disease progression. These fast readouts are stronger and more actionable, so can help companies decide quickly whether or not a drug is working and which patient is responding.”

KineMed’s neuro-biomarker program aims to develop robust, lead indicators of disease progression and regression through identifying and measuring relevant biochemical changes associated with pathology at the cellular level.

These quantitative measures can replace cumbersome symptomatic measures that are sensitive to random fluctuation in the patient’s condition, which are hindering and expanding the cost of trials of CNS drugs in development.

The length and cost of developing a CNS drug is among the highest of any therapeutic area.

A 2011 study by The Tufts Center for the Study of Drug Development reported that an average of 8.1 years was spent in human testing-more than two years longer and more than 50 percent longer in the regulatory approval stage compared with drugs on average.

The study also reported that only 8.2 percent of CNS drug candidates that begin human testing reach the marketplace, compared with 15 percent for drugs overall.

KineMed leads the world in measuring dynamic biochemical processes important in the pathogenesis of the central and peripheral nervous system to identify and verify kinetic marker candidates.

KineMed’s neuro-biomarker platform is unique, in that it reveals the kinetics of molecules through critical processes that drive neuronal dysfunction, disease progression and reparative processes.

These biomarkers thereby predict outcomes and provide key information for disease-modifying drugs in development for neurological disorders.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

KineMed, Pfizer Launch Collaboration
KineMed has announced that it has entered into a strategic collaboration with Pfizer to discover and develop novel proprietary biomarkers in various fields of unmet medical need.
Tuesday, January 05, 2016
KineMed and Amgen to Develop Kinetic Biomarkers of Brain Proteinopathies
KineMed’s biomarker platform will allow Amgen to track synthesis and clearance rates of pathogenic proteins in the brain that drive neurodegeneration.
Tuesday, October 15, 2013
Pfizer-KineMed Collaboration Extends to Target Novel Diabetes Pathways
KineMed Inc. announced the renewal of a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes.
Thursday, March 28, 2013
KineMed and CHDI Foundation Collaborate
KineMed’s isotopic labeling technology and analytical expertise will be applied to measure in vivo production rates of huntingtin protein as a potential biomarker of disease state.
Thursday, May 17, 2012
Scientific News
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!